Alnylam Pharma (ALNY) Misses Q3 EPS by 42c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $291.37 -0.61%
EPS Growth %: +409.4%
Financial Fact:
General and administrative: 17.99M
Today's EPS Names:
CGEH, NAKA, APOG, More
EPS Growth %: +409.4%
Financial Fact:
General and administrative: 17.99M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($2.43), $0.42 worse than the analyst estimate of ($2.01). Revenue for the quarter came in at $2.07 million versus the consensus estimate of $18.23 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Farmmi announces public offering of Class A ordinary shares
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
